Ocugen, Inc.

NASDAQ:OCGN

Biotechnology

Healthcare
$0.74 +2.46%

+$0.03 today

Market cap
$250.82M
Beta
2.21
P/E (TTM)
-5.6
EPS (TTM)
-$0.22
52W Low $0.90High $2.73

Volume 5.83M

Average 7.51M

OCGN Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Ocugen, Inc.NASDAQ: OCGN

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 32.4% from a year ago

Deferred revenue stood at $5.21M at the end of Q1 FY2026, down 32.4% from a year earlier and down 11.8% from the prior quarter. Over 3 fiscal years it compounded at -19.3% a year.

Context

  • Deferred revenue amounted to 9.2% of total assets at the end of Q1 FY2026, down 2.8 pp from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -32.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.21M-11.8% QoQ
Last fiscal yearDec 2025
$5.91M-29.4% YoY
Year agoMar 2025
$7.7M-32.4% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.4%——
1 year-29.4%——
3-year CAGR-19.3%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
5.91M USD
Year-over-year change
-29.4%

Deferred Revenue vs competitors

How OCGN compares with its peers on the latest reported figures

  • OCGN's Mar 2026 deferred revenue of $5.21M is the 2nd highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -32.4% is the highest of 3, against a peer median of -87.6%.
  • Deferred revenue amounts to 9.2% of total assets for OCGN, versus a peer median of 0.0%.
OCGN Competitors Peer median
Deferred Revenue for OCGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALMSAlumis Inc. Common StockJun 2026$6.67M ——1.2%
OCGNOcugen, Inc.Mar 2026$5.21M -32.4%-19.3%9.2%
OMEROmeros CorporationMar 2026$2.82M ——1.0%
LCTXLineage Cell Therapeutics, Inc.Mar 2026$1.72M -75.2%-29.3%1.6%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
NGNENeurogene Inc.Mar 2026$0 ——0.0%
FULCFulcrum Therapeutics, Inc.Mar 2026$0 ——0.0%
ADCTADC Therapeutics S.A.Mar 2026$0 ——0.0%
CMPXCompass Therapeutics, Inc.Mar 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding OCGN) $0-87.6%-29.3%0.0%

Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents94.96M77.56M39.46M58.51M18.57M
Short-term Investments013.37M000
Net Receivables00000
Inventory00000
Other Current Assets07.56M3.51M3.17M5.77M
Total Current Assets102.65M98.49M42.97M61.68M24.34M
Property, Plant & Equipment (Net)1.16M6.05M17.29M16.55M14.39M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.95M4.09M4.29M4.21M4.78M
Total Non-current Assets3.12M10.14M21.58M20.76M19.18M
Total Assets105.76M108.63M64.55M82.44M43.52M
Account Payables2.31M8.06M3.17M4.24M6.2M
Short-term Debt0001.33M1.25M
Tax Payables00000
Deferred Revenue011.22M10.53M8.37M5.91M
Other Current Liabilities1.72M3.11M1.03M5.26M6.69M
Total Current Liabilities7M28.53M17.09M21.59M23.04M
Long-term Debt1.71M2.29M2.8M27.35M27.54M
Deferred Tax Liabilities00918K00
Deferred Revenue (Non-current)00(918K)00
Other Non-current Liabilities0244K527K564K1.6M
Total Non-current Liabilities2.94M6.12M6.89M31.22M32.64M
Total Liabilities9.94M34.65M23.98M52.81M55.68M
Common Stock2M2.22M2.57M2.92M3.13M
Retained Earnings(131.67M)(223.09M)(286.17M)(340.22M)(408.07M)
Accumulated OCI(0)26K20K48K61K
Other Stockholders Equity00000
Minority Interest00000
Total Equity95.82M73.98M40.56M29.63M(12.17M)
Total Debt3.31M6.37M6.94M32.5M33.14M
Net Debt(91.65M)(71.19M)(32.52M)(26.01M)14.57M

Ocugen, Inc.

NASDAQ:OCGN

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.